Sign in to register to receive emails with product information.
The RapidFire® mass spectrometry platform enables label-free high-throughput screening for use in drug discovery for lead identification and in vitro ADME analysis. RapidFire's mass spectrometry based technology facilitates the direct quantitation of native analytes in seconds per sample, providing mass spec quality data at speeds approaching that of a plate reader. Patented RapidFire technology involves microscale solid-phase extraction coupled to elegant control software which enables unprecedented speeds for mass spectrometry analysis. The RapidFire system is uniquely positioned for high throughput screening of intractable targets those that are challenging to analyze using traditional methods - in an ever-expanding variety of therapeutic areas, such as metabolic disease, epigenetics, cardiovascular disease, anti-fungals and anti-infectives, inflammation, CNS disorders, and oncology. Used by 13 of the top 15 pharmaceutical companies, the RapidFire platform from BIOCIUS enables faster and more efficient drug discovery decisions.